Want to see HLYK full AI Analyst Report?
Top Page
HealthLynked
(OTC:HLYK)
Select Model
Select Model
Rating:43Neutral
Price Target:
$2.50
▼(-9.09% Downside)
Action:Reiterated
Date:08/21/26
The score is primarily constrained by weak financial performance—shrinking revenue, large ongoing losses, persistent cash burn, and a strained balance sheet with negative equity and high leverage. Technicals add a modestly negative tilt with the stock trading below major moving averages and a negative MACD, while valuation is not supportive given the negative P/E and no dividend yield.
Positive Factors
High Gross Margin
The very high gross margin suggests the platform can retain substantial revenue after direct costs. If the company can rebuild demand and control operating expenses, this cost structure could support improved profitability over time.
Negative Factors
Sustained Revenue Contraction
The prolonged decline in revenue signals weakening commercial traction and a shrinking operating base. Without renewed customer adoption or stronger monetization, fixed costs will remain difficult to absorb and recovery will be constrained.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
The very high gross margin suggests the platform can retain substantial revenue after direct costs. If the company can rebuild demand and control operating expenses, this cost structure could support improved profitability over time.
Read all positive factors
HealthLynked (HLYK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.60M
Dividend YieldN/A
Average Volume (3M)874.00
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue Growth-46.73%
EPS Growth21.91%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,953,225
10 Day Avg. Volume506
30 Day Avg. Volume874
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.69
Price to Sales (P/S)1.92
P/FCF Ratio-2.32
Enterprise Value/Market Cap2.20
Enterprise Value/Revenue12.19
Enterprise Value/Gross Profit12.44
Enterprise Value/Ebitda-5.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HealthLynked Business Overview & Revenue Model
Company Description
HealthLynked Corporation operates a digital platform in the United States for the management and archiving of patient information, utilizing cloud technology. The company's business activities are organized into four main segments: Health Services...
How the Company Makes Money
null...
HealthLynked Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.37M | 2.07M | 3.01M | 5.72M | 5.86M | 9.20M |
| Gross Profit | 1.34M | 2.01M | 2.91M | 2.35M | 5.40M | 6.18M |
| EBITDA | -3.19M | -2.13M | -4.36M | -2.75M | -7.05M | -9.85M |
| Net Income | -3.97M | -3.28M | -6.13M | -1.01M | -8.82M | -10.41M |
Balance Sheet | ||||||
| Total Assets | 1.59M | 1.70M | 2.22M | 4.28M | 4.58M | 10.69M |
| Cash, Cash Equivalents and Short-Term Investments | 12.84K | 37.14K | 76.24K | 247.22K | 61.89K | 3.29M |
| Total Debt | 8.08M | 5.83M | 997.85K | 1.97M | 1.28M | 978.19K |
| Total Liabilities | 9.35M | 7.46M | 5.35M | 3.48M | 4.27M | 3.49M |
| Stockholders Equity | -7.75M | -5.76M | -3.13M | 804.73K | 314.45K | 7.20M |
Cash Flow | ||||||
| Free Cash Flow | -2.30M | -1.71M | -3.50M | -4.15M | -4.39M | -3.79M |
| Operating Cash Flow | -2.30M | -1.71M | -3.49M | -4.14M | -4.36M | -3.77M |
| Investing Cash Flow | 125.00K | 125.00K | 422.40K | 3.51M | -544.75K | -341.36K |
| Financing Cash Flow | 1.30M | 1.55M | 2.90M | 824.09K | 1.68M | 7.24M |
HealthLynked Technical Analysis
Negative
2.75
Price Trends
2.88
Negative
2.78
Negative
2.91
Negative
Market Momentum
-0.05
Negative
43.19
Neutral
21.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HLYK, the sentiment is Negative. The current price of 2.75 is above the 20-day moving average (MA) of 2.64, below the 50-day MA of 2.88, and below the 200-day MA of 2.91, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 43.19 is Neutral, neither overbought nor oversold. The STOCH value of 21.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HLYK.
HealthLynked Risk Analysis
HealthLynked disclosed 36 risk factors in its most recent earnings report. HealthLynked reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
HealthLynked Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $1.32B | 7.37 | 51.88% | ― | 6.88% | 155.98% | |
58 Neutral | $67.89M | -0.28 | 160.54% | ― | 2.81% | 26.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $39.84M | -0.21 | -115.58% | ― | -32.40% | -969.05% | |
43 Neutral | $7.60M | -1.89 | 61.14% | ― | -46.73% | 21.91% | |
38 Underperform | $1.70M | -0.02 | -46.21% | ― | -35.26% | 51.06% |
* Healthcare Sector Average
HLYK
HealthLynked
2.58
0.28
11.96%
NUTX
Clinigence Holdings
193.24
109.83
131.67%
DCGO
DocGo
0.40
-1.17
-74.39%
PIII
P3 Health Partners
9.35
0.57
6.49%
MNDR
Mobile-health Network Solutions Class A
1.42
-22.66
-94.10%
HealthLynked Corporate Events
Business Operations and StrategyExecutive/Board Changes
HealthLynked Restructures Executive Team, Names Interim CFO
Neutral
Jul 17, 2026
Effective July 13, 2026, HealthLynked appointed long-time director and former CFO George O’Leary as part-time Interim Chief Financial Officer, working three days a week for $15,000 per month and receiving performance-based stock options tied...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.